Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial
Table 2
Overview of adverse events (AEs) and adverse drug reactions (ADRs) that occurred during the study period in the safety collective.
Echinaforce ()
Placebo ()
Total ()
Number (%) of participants with
(i) adverse events
177 (49.9)
172 (47.5)
349 (48.7)
(ii) drug-related AEs1
35 (9.9)
35 (9.7)
70 (9.8)
(iii) serious AEs
0 (0.0)
1 (0.3)
1 (0.1)
(iv) AEs leading to treatment discontinuation
3 (0.8)
2 (0.6)
5 (0.7)
Number of events2
(i) adverse events
293
306
599
(ii) drug-related AEs1
39
36
75
(iii) serious adverse events
0
1
1
(iv) AEs leading to treatment discontinuation
4
3
7
1AEs that were causally related to the study medication with ratings of certain, probable/likely, or possible. 2AEs were based on the Preferred Terms (PTs), each PT counted only once per participant.